Improving Access to Rare Disease Treatments: Subsidy, Pricing, and Payment Schemes

Wendy Olsder (), Tugce Martagan () and Christopher S. Tang ()
Additional contact information
Wendy Olsder: School of Industrial Engineering, Eindhoven University of Technology, 5612 AZ Eindhoven, The Netherlands; Erasmus School of Health Policy & Management, 3062 PA Rotterdam, Netherlands
Tugce Martagan: School of Industrial Engineering, Eindhoven University of Technology, 5612 AZ Eindhoven, The Netherlands
Christopher S. Tang: Anderson School, University of California, Los Angeles, California 90095

Management Science, 2023, vol. 69, issue 9, 5256-5274

Abstract: There are more than 7,000 known rare diseases, but pharmaceutical manufacturers developed treatments for only 500 of them. To improve the availability and accessibility of treatments for rare diseases, governments have introduced several programs including subsidies, exogenous pricing, and outcome-based payment schemes in recent years. What kind of subsidy programs and pricing mechanisms can improve patient access? Inspired by various pilot programs, we present a multistage game theoretic model to analyze different subsidy schemes proposed for rare diseases. In addition to the traditional setting in which the manufacturer sets the price, we consider an “exogenous pricing scheme” under which an independent consortium sets the price. We also examine an outcome-based payment scheme, which offers the drug for free if it is not efficacious. We formulate a four-stage Stackelberg game to determine whether it is optimal to subsidize the pharmaceutical manufacturer, the patients, or both. Our results offer several insights. First, we find that government subsidies are crucial to entice new drug development for rare diseases. Also, we find that the pricing scheme matters: The exogenous pricing scheme can improve patient welfare, but it reduces the manufacturer’s expected profit. We find that this result is robust even when an outcome-based payment scheme is used.

Keywords: government subsidy schemes; rare diseases; orphan drugs; patient welfare; exogenous pricing scheme; outcome-based payment (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
http://dx.doi.org/10.1287/mnsc.2022.4634 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:inm:ormnsc:v:69:y:2023:i:9:p:5256-5274

Access Statistics for this article

More articles in Management Science from INFORMS Contact information at EDIRC.
Bibliographic data for series maintained by Chris Asher ().